Medivation, Inc. (MDVN) is on the rise during Monday's after-hours trading following news that its investigational drug Dimebon significantly improved cognitive function in patients with mild-to-moderate Huntington's disease.
At 4:32 pm ET the stock is trading at $14.50 up $2.39 from Monday's close.
With the advance, the stock stands to open having halted a recent downtrend and at its highest level in nearly a month.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.